CNBC Television published this video item, entitled “Eli Lilly CEO on Q2 earnings and core business performance” – below is their description.
Eli Lilly CEO David Ricks joins ‘Squawk Box’ to discuss the company’s second quarter earnings and his outlook for the business. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi
Drugmaker Eli Lilly fell short of quarterly profit expectations on Tuesday, as persistent regulatory actions in the United States and lower demand hurt sales of its Covid-19 therapies.
The distribution of its antibody cocktail was paused by the U.S. health officials in late June after lab analyses showed it was not effective against variants first identified in Brazil and South Africa.
Hospitals have also struggled with administering the drugs bamlanivimab and etesevimab, slowing its sales, which have further been dented by vaccine rollouts in the United States.
The U.S. health regulator have also denied the lone use of bamlanivimab to treat Covid-19 in response to variants that could be resistant to the treatment.
Shares of the company fell 2% before the bell after it lowered the upper end of its annual sales forecast for the therapies to $1.1 billion, from its prior view of between $1 billion and $1.5 billion.
Sales of its antibody treatments came in at $148.9 million in the quarter compared to $810.1 million in the previous quarter.
However, sales of its blockbuster diabetes drug Trulicity rose 25% to $1.54 billion, roughly in line with estimates of $1.53 billion.
Other growth drivers such as psoriasis drug Taltz also exceeded market expectations, but sales of some diabetes treatments missed the Wall Street targets.
Sales of insulin injection Humalog rose 9% to $607.6 million, but missed estimates of $622.14 million.
Net income fell to $1.39 billion in the quarter ended June 30 from $1.41 billion a year ago.
Excluding items, Lilly earned $1.87 per share, missing estimates of $1.89 per share, according to Refinitiv IBES data
The drugmaker said it plans to submit a marketing application for its experimental Alzheimer’s drug, donanemab, by the end of this year.
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-news-with-shepard-smith-podcast.html?__source=youtube%7Cshepsmith%7Cpodcast
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC
#CNBCTVCNBC Television YouTube Channel
Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.